AirSculpt Technologies, Inc. — Q2 2023 Form 10-Q
Reporting period: Three and six months ended June 30, 2023; comparisons are with the corresponding 2022 periods. AirSculpt provides practice-management services supporting minimally invasive body-contouring procedures. Its results consolidate affiliated professional associations. Financial amounts below are in millions unless noted.
Financial performance
| Metric | Q2 2023 | Q2 2022 | First half 2023 | First half 2022 |
|---|---|---|---|---|
| Revenue | $55.7 | $49.7 | $101.5 | $89.2 |
| Operating income | $5.4 | $4.0 | $7.1 | $2.8 |
| Net income/(loss) | $1.8 | $0.6 | $1.8 | $(0.1) |
| Net margin | 3.2% | 1.2% | 1.7% | (0.1)% |
| Adjusted EBITDA (non-GAAP) | $14.6 | $14.0 | $24.1 | $22.9 |
| Adjusted EBITDA margin (non-GAAP) | 26.2% | 28.1% | 23.7% | 25.7% |
Revenue grew 12.2% in Q2 and 13.8% in the first half. Growth was attributed primarily to six new centers, taking the count from 19 to 25 at June 30; 26 centers were reported as of August 11. Total cases rose 13.4% in Q2 and 14.3% in the first half. Revenue per case decreased 1.1% in Q2 and 0.4% in the first half. Same-center cases declined 2.8% in Q2 and 1.3% in the first half.
Cost of service was 35.8% of Q2 revenue, versus 35.2% a year earlier; for the first half it was 37.4%, versus 36.0%. Management cited the higher initial costs of new centers, which may take up to two years to mature. SG&A was 50.1% of Q2 revenue (52.4% prior year) and 51.0% for the first half (56.3% prior year). GAAP operating margin was 9.6% in Q2 and 7.0% for the first half. The filing does not present a labeled gross-margin measure; cost-of-service percentages are shown above.
Cash, debt and liquidity
- Operating cash flow was $18.5 million for the first half, compared with $17.5 million; capital spending was $6.0 million, compared with $6.1 million. Cash increased $11.2 million to $20.8 million.
- At June 30, current assets were $26.8 million and current liabilities $23.9 million, yielding reported working capital of approximately $2.9 million. The company also had $5.0 million available under its revolving facility.
- Debt carrying value, net of financing costs, was $83.0 million; term-loan principal was $83.9 million. The loan matures in November 2027, bears a floating rate, and is secured by substantially all company assets. The filing reports the June 30 rate as 7.23% in the debt note but 7.65% in MD&A; the reported value is inconsistent.
- Management said operating cash generation and the revolver should cover working capital, planned center investment, and debt payments for at least the next 12 months. The company reported compliance with debt covenants and no revolver borrowings.
Outlook, risks and notable items
No quantified financial guidance was provided. Management expects marketing and corporate-support costs to rise as it opens centers and expands support, and intends to continue investing in sales and marketing. The filing describes new-center expansion and procedure-room additions as ongoing capital needs.
Key disclosed risks include opening centers on time and cost-effectively; supplier shortages or quality issues; competition for surgeons; malpractice and other litigation; regulatory changes affecting medical practice or fee-splitting; and macroeconomic conditions, including inflation and recession risk. Ordinary-course legal claims, including medical-malpractice matters, were described as not expected to have a material adverse effect, but outcomes and insurance sufficiency cannot be assured.
Unusual or notable items include $2.2 million of Q2 restructuring and related severance costs and $3.3 million for the first half, both included as add-backs in the company’s non-GAAP Adjusted EBITDA reconciliation. Equity-based compensation was $4.6 million in Q2 and $9.0 million in the first half. The company reported effective tax rates of 48.8% for Q2 and 49.6% for the first half, citing nondeductible executive compensation as a principal driver. Disclosure controls were assessed as effective at a reasonable-assurance level; no material change in internal controls was reported.
Important facts for investors to verify
- Reconcile the conflicting disclosed June 30 borrowing rates of 7.23% and 7.65%, and assess exposure to floating rates and covenant requirements.
- Track same-center case trends and revenue per case against growth from newly opened centers.
- Monitor whether new centers mature as expected and how expansion affects service costs, cash needs, and profitability.
- Review non-GAAP adjustments, especially recurring equity compensation and restructuring costs, alongside GAAP earnings and cash flow.
- Assess professional-liability claims and whether insurance will adequately cover unfavorable outcomes.